<?xml version='1.0' encoding='utf-8'?>
<document id="24079718"><sentence text="Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor." /><sentence text="Two clinical trials and a large set of in vitro transporter experiments were performed to investigate if the hepatobiliary disposition of the direct thrombin inhibitor prodrug AZD0837 is the mechanism for the drug-drug interaction with ketoconazole observed in a previous clinical study"><entity charOffset="236-248" id="DDI-PubMed.24079718.s2.e0" text="ketoconazole" /></sentence><sentence text=" In Study 1, [(3)H]AZD0837 was administered to healthy male volunteers (n = 8) to quantify and identify the metabolites excreted in bile" /><sentence text=" Bile was sampled directly from the jejunum by duodenal aspiration via an oro-enteric tube" /><sentence text=" In Study 2, the effect of ketoconazole on the plasma and bile pharmacokinetics of AZD0837, the intermediate metabolite (AR-H069927), and the active form (AR-H067637) was investigated (n = 17)"><entity charOffset="27-39" id="DDI-PubMed.24079718.s5.e0" text="ketoconazole" /></sentence><sentence text=" Co-administration with ketoconazole elevated the plasma exposure to AZD0837 and the active form approximately 2-fold compared to placebo, which may be explained by inhibited CYP3A4 metabolism and reduced biliary clearance, respectively"><entity charOffset="24-36" id="DDI-PubMed.24079718.s6.e0" text="ketoconazole" /></sentence><sentence text=" High concentrations of the active form was measured in bile with a bile-to-plasma AUC ratio of approximately 75, indicating involvement of transporter-mediated excretion of the compound" /><sentence text=" AZD0837 and its metabolites were further investigated as substrates of hepatic uptake and efflux transporters in vitro" /><sentence text=" Studies in MDCK-MDR1 cell monolayers and P-glycoprotein (P-gp) expressing membrane vesicles identified AZD0837, the intermediate, and the active form as substrates of P-gp" /><sentence text=" The active form was also identified as a substrate of the multidrug and toxin extrusion 1 (MATE1) transporter and the organic cation transporter 1 (OCT1), in HEK cells transfected with the respective transporter" /><sentence text=" Ketoconazole was shown to inhibit all of these three transporters; in particular, inhibition of P-gp and MATE1 occurred in a clinically relevant concentration range"><entity charOffset="1-13" id="DDI-PubMed.24079718.s11.e0" text="Ketoconazole" /></sentence><sentence text=" In conclusion, the hepatobiliary transport pathways of AZD0837 and its metabolites were identified in vitro and in vivo" /><sentence text=" Inhibition of the canalicular transporters P-gp and MATE1 may lead to enhanced plasma exposure to the active form, which could, at least in part, explain the clinical interaction with ketoconazole"><entity charOffset="185-197" id="DDI-PubMed.24079718.s13.e0" text="ketoconazole" /></sentence><sentence text=" " /></document>